Common Contracts
6 similar First Supplemental Indenture contracts by Celgene Corp /De/
CELGENE CORPORATION, as Issuer, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 1, 2019 to INDENTUREFirst Supplemental Indenture • July 30th, 2019 • Celgene Corp /De/ • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of May 1, 2019 (this “First Supplemental Indenture”), between Celgene Corporation, a Delaware corporation (herein called the “Company”), having its principal executive offices at 86 Morris Avenue, Summit, New Jersey 07901, and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (herein called the “Trustee”).
CELGENE CORPORATION, as Issuer, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 1, 2019 to INDENTUREFirst Supplemental Indenture • July 30th, 2019 • Celgene Corp /De/ • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of May 1, 2019 (this “First Supplemental Indenture”), between Celgene Corporation, a Delaware corporation (herein called the “Company”), having its principal executive offices at 86 Morris Avenue, Summit, New Jersey 07901, and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (herein called the “Trustee”).
CELGENE CORPORATION, as Issuer, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 1, 2019 to INDENTUREFirst Supplemental Indenture • July 30th, 2019 • Celgene Corp /De/ • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of May 1, 2019 (this “First Supplemental Indenture”), between Celgene Corporation, a Delaware corporation (herein called the “Company”), having its principal executive offices at 86 Morris Avenue, Summit, New Jersey 07901, and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (herein called the “Trustee”).
CELGENE CORPORATION, as Issuer, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 1, 2019 to INDENTUREFirst Supplemental Indenture • July 30th, 2019 • Celgene Corp /De/ • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of May 1, 2019 (this “First Supplemental Indenture”), between Celgene Corporation, a Delaware corporation (herein called the “Company”), having its principal executive offices at 86 Morris Avenue, Summit, New Jersey 07901, and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (herein called the “Trustee”).
CELGENE CORPORATION, as Issuer, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 1, 2019 to INDENTUREFirst Supplemental Indenture • July 30th, 2019 • Celgene Corp /De/ • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of May 1, 2019 (this “First Supplemental Indenture”), between Celgene Corporation, a Delaware corporation (herein called the “Company”), having its principal executive offices at 86 Morris Avenue, Summit, New Jersey 07901, and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (herein called the “Trustee”).
CELGENE CORPORATION, as Issuer, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 1, 2019 to INDENTUREFirst Supplemental Indenture • July 30th, 2019 • Celgene Corp /De/ • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of May 1, 2019 (this “First Supplemental Indenture”), between Celgene Corporation, a Delaware corporation (herein called the “Company”), having its principal executive offices at 86 Morris Avenue, Summit, New Jersey 07901, and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (herein called the “Trustee”).
